Hypothalamic dysfunction from paternally imprinted gene deletions is the main pathogenesis of PWS and is characterized by short stature, infantile hypotonia, hypothalamic hypogonadism, excessive appetite, and progressive obesity [1,2]
It may support: Reduction in visceral and subcutaneous fat Enhanced lipolysis during exercise Support for metabolic inflexibility or plateau states in fat loss programs 2
Source: #Healthcare #Pharma #GLP1 #Obesity #HealthPolicy #Innovation GLP-1 drugs for obesity: Cost-effective, but coverage uncertain As reported by Axios International Vitals, the leading GLP-1 drugs from Novo Nordisk and Eli Lilly and Company are now becoming cost-effective for treating obesity, according to a new analysis from the Institute for Clinical and Economic Review (ICER): Why does this matter
"Usually, the first line of treatment is to have a regular bedtime," said McGlinchey, since sleep terrors can often start with sleep deprivation
At Mission Connection, we help adults and teens facing new and pre-existing mental health challenges, including those related to weight and body image
